KR20250129720A - 이중특이적 단백질을 생성하는 방법 - Google Patents

이중특이적 단백질을 생성하는 방법

Info

Publication number
KR20250129720A
KR20250129720A KR1020257024695A KR20257024695A KR20250129720A KR 20250129720 A KR20250129720 A KR 20250129720A KR 1020257024695 A KR1020257024695 A KR 1020257024695A KR 20257024695 A KR20257024695 A KR 20257024695A KR 20250129720 A KR20250129720 A KR 20250129720A
Authority
KR
South Korea
Prior art keywords
protein
antibody
heterodimeric
domain
igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257024695A
Other languages
English (en)
Korean (ko)
Inventor
코르넬리스 아드리아안 드 크루이프
프란지스카 모르텐센
Original Assignee
메뤼스 엔.페.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메뤼스 엔.페. filed Critical 메뤼스 엔.페.
Publication of KR20250129720A publication Critical patent/KR20250129720A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020257024695A 2022-12-27 2023-12-22 이중특이적 단백질을 생성하는 방법 Pending KR20250129720A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2033843 2022-12-27
NL2033843 2022-12-27
PCT/NL2023/050681 WO2024144396A1 (en) 2022-12-27 2023-12-22 Method for generating bispecific proteins

Publications (1)

Publication Number Publication Date
KR20250129720A true KR20250129720A (ko) 2025-08-29

Family

ID=85158672

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257024695A Pending KR20250129720A (ko) 2022-12-27 2023-12-22 이중특이적 단백질을 생성하는 방법

Country Status (8)

Country Link
EP (1) EP4642811A1 (enExample)
JP (1) JP2026500710A (enExample)
KR (1) KR20250129720A (enExample)
CN (2) CN120641444A (enExample)
AU (1) AU2023418349A1 (enExample)
IL (1) IL321671A (enExample)
TW (1) TW202432587A (enExample)
WO (1) WO2024144396A1 (enExample)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
US5151504A (en) 1989-11-17 1992-09-29 E. R. Squibb & Sons, Inc. Method for purification of monoclonal antibodies
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
DK2771364T3 (da) * 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
SG11202009036YA (en) 2018-03-30 2020-10-29 Merus Nv Multivalent antibody
MA55884A (fr) 2019-05-09 2022-03-16 Merus Nv Domaines variants pour la multimérisation de protéines et leur séparation
KR20230013030A (ko) 2020-05-21 2023-01-26 메뤼스 엔.페. Ig-유사 분자의 생산을 위한 방법 및 수단

Also Published As

Publication number Publication date
CN121824747A (zh) 2026-04-10
AU2023418349A1 (en) 2025-07-03
IL321671A (en) 2025-08-01
TW202432587A (zh) 2024-08-16
EP4642811A1 (en) 2025-11-05
WO2024144396A1 (en) 2024-07-04
JP2026500710A (ja) 2026-01-08
CN120641444A (zh) 2025-09-12

Similar Documents

Publication Publication Date Title
CN110256569B (zh) 具有交换结合区取向的双重可变区抗体样结合蛋白
JP7373650B2 (ja) 抗ｐｄ－ｌ１シングルドメイン抗体
IL274735A (en) Compositions and methods related to engineered fc constructs
CN110913904A (zh) 用于改善的储存和施用的包含双特异性抗体构建体的药物组合物
JP7760377B2 (ja) タンパク質を多量体化する変異体ドメイン及びその分離
CN110382537B (zh) 抗体结构域的优选配对
JP2025063025A (ja) Ｉｇ様分子の製造のための方法および手段
KR20230141817A (ko) 이중특이 항체
WO2022089569A1 (en) Modified soluble t cell receptor
JP2025506341A5 (enExample)
CN112789058A (zh) 双特异性抗体构建体的下游加工
CA3232365A1 (en) Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof in hiv
AU2021242058A1 (en) Method for creating multimeric IgA antibody, and multispecific multimeric IgA antibody
JP2026500710A (ja) 二重特異性タンパク質を製造する方法
JP7686626B2 (ja) 増強されたプロテインｌ捕捉動的結合容量を有する二重特異性抗原結合ポリペプチドの精製方法
JP2024534976A (ja) Ｍｈｃタンパク質に基づくヘテロ二量体を含む二重特異性抗体
TWI918721B (zh) Egfr結合複合物及其製備和使用方法
US20260098094A1 (en) Cµ4 REGION FOR PAIRING HEAVY AND LIGHT CHAINS IN MULTI-SPECIFIC ANTIBODIES
JP2025528101A (ja) 多重特異性ポリペプチド複合体
KR20250169614A (ko) 최적화된 cd3 항원 결합 도메인
Khalili Disulfide-bridging PEGylation of antibody fragments

Legal Events

Date Code Title Description
E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)